Výsledky vyhledávání

IntroductionDespite advances in treating high-risk neuroblastoma, 50-60% of patients still suffer relapse, necessitating new treatment options. Bispecific trifunctional antibodies (trAbs) are a promising new class of immunotherapy. TrAbs are heterodi

Externí odkaz: https://doaj.org/article/4e199ae7fd1b49e29afc664c4e0bbbe6

Zobrazit plný text záznamu

Akademický článek

Removal of EpCAM-positive tumor cells from blood collected during major oncological surgery using the Catuvab device- a pilot study

Autor: Andreas Winter, Kai Zacharowski, Patrick Meybohm, Andreas Schnitzbauer, Peter Ruf, Claudia Kellermann, Horst Lindhofer

Publikováno v: BMC Anesthesiology, Vol 21, Iss 1, Pp 1-11 (2021)

Abstract Background Intraoperative blood salvage (IBS) is regarded as an alternative to allogeneic blood transfusion excluding the risks associated with allogeneic blood. Currently, IBS is generally avoided in tumor surgeries due to concern for poten

Externí odkaz: https://doaj.org/article/ba1d02f44a6647b1b000b90124923843

Zobrazit plný text záznamu

Akademický článek

GD2-directed bispecific trifunctional antibody outperforms dinutuximab beta in a murine model for aggressive metastasized neuroblastoma

Autor: Annette Künkele, Angelika Eggert, Johannes H Schulte, Anika Klaus, Horst Lindhofer, Felix Zirngibl, Sara M Ivasko, Laura Grunewald, Silke Schwiebert, Peter Ruf, Kathy Astrahantseff, Lena Andersch, Holger N Lode, Kathleen Anders, Patrick Hundsdoerfer

Publikováno v: Journal for ImmunoTherapy of Cancer, Vol 9, Iss 7 (2021)

Background Neuroblastoma is the most common extracranial solid tumor of childhood. Patients with high-risk disease undergo extremely aggressive therapy and nonetheless have cure rates below 50%. Treatment with the ch14.18 monoclonal antibody (dinutux

Externí odkaz: https://doaj.org/article/3775a0fe4d3545de91f6ca37d90c877c

Zobrazit plný text záznamu

Data from Efficacy and Tolerability of a GD2-Directed Trifunctional Bispecific Antibody in a Preclinical Model: Subcutaneous Administration Is Superior to Intravenous Delivery

Autor: Ralph Mocikat, Horst Lindhofer, Raymund Buhmann, Frauke Neff, Nina Eissler, Peter Ruf, Nina Deppisch

Trifunctional bispecific antibodies (trAb) are novel anticancer drugs that recruit and activate different types of immune effector cells at the targeted tumor. Thus, tumor cells are effectively eliminated and a long-lasting tumor-specific T-cell memo

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::251f0d06a62bf4124467a82046de7771
https://doi.org/10.1158/1535-7163.c.6538330.v1

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání